<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00286793</url>
  </required_header>
  <id_info>
    <org_study_id>AT-101-CS-202</org_study_id>
    <nct_id>NCT00286793</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With HRPC</brief_title>
  <official_title>An Open-label, Multicenter, Phase I/II Study of AT-101 in Combination With Docetaxel and Prednisone in Men With Hormone Refractory Prostate Cancer (HRPC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ascenta Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ascenta Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multicenter Phase I/II study to evaluate the safety and efficacy of&#xD;
      AT-101 in combination with docetaxel and prednisone in men with hormone-refractory prostate&#xD;
      cancer that are either chemotherapy naive or have received and progressed on a docetaxel&#xD;
      containing regimen,&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of AT-101 in combination with docetaxel and prednisone</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Preliminary efficacy of AT-101 in combination with docetaxel and prednisone</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>SIngle Arm Study of AT-101 in combination with Docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AT-101</intervention_name>
    <description>Oral</description>
    <arm_group_label>SIngle Arm Study of AT-101 in combination with Docetaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Rising prostate specific antigen (PSA) despite castrate levels of testosterone due to&#xD;
             orchiectomy or luteinizing hormone-releasing hormone (LHRH) agonist therapy.&#xD;
&#xD;
          2. Patients must have metastatic disease by bone scan, computed tomography (CT) scan, or&#xD;
             magnetic resonance imaging (MRI).&#xD;
&#xD;
          3. ECOG performance status 0 or 1&#xD;
&#xD;
          4. Adequate hematologic function&#xD;
&#xD;
          5. Adequate liver and renal function&#xD;
&#xD;
          6. Able to swallow and retain oral medication.&#xD;
&#xD;
          7. Patients enrolled into Cohort B must have documented progression of disease during&#xD;
             treatment with a docetaxel-containing regimen by meeting one or more of the following&#xD;
             criteria- rising PSA, progression of disease per RECIST, or &gt;2 new lesions on bone&#xD;
             scan.&#xD;
&#xD;
          8. Patients enrolled into Cohort B must have received at least two cycles of docetaxel.&#xD;
             Minimum doses of prior docetaxel permitted are 60 mg/m2 on a q 3 week schedule or 20&#xD;
             mg/m2 on a weekly schedule.&#xD;
&#xD;
          9. At least 4 weeks since prior flutamide, megestrol, ketoconazole, and radiotherapy, and&#xD;
             at least 6 weeks since prior bicalutamide or nilutamide.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients enrolled into Cohort A must not have received prior chemotherapy for HRPC.&#xD;
&#xD;
          2. Known history of or clinical evidence of central nervous system (CNS) metastases.&#xD;
&#xD;
          3. Active secondary malignancy or history of other malignancy within the last 5 years.&#xD;
&#xD;
          4. Prior history of radiation therapy to &gt; 25% of the bone marrow&#xD;
&#xD;
          5. Peripheral neuropathy of &gt; Grade 2&#xD;
&#xD;
          6. Uncontrolled concurrent illness&#xD;
&#xD;
          7. Failure to recover fully, as judged by the investigator, from prior surgical&#xD;
             procedures.&#xD;
&#xD;
          8. Concurrent anti-cancer therapy other than docetaxel and prednisone.&#xD;
&#xD;
          9. Patients must not be receiving concurrent anti-androgen hormonal therapy for HRPC&#xD;
             (LHRH therapies are acceptable to maintain castrate levels of testosterone)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lance Leopold, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ascenta Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Meyers</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hilton Head Island</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richardson</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <study_first_submitted>February 3, 2006</study_first_submitted>
  <study_first_submitted_qc>February 3, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2006</study_first_posted>
  <disposition_first_submitted>June 27, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>June 27, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 29, 2011</disposition_first_posted>
  <last_update_submitted>June 27, 2011</last_update_submitted>
  <last_update_submitted_qc>June 27, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 29, 2011</last_update_posted>
  <responsible_party>
    <name_title>Kimberli Brill, Associate Director, Clinical Development</name_title>
    <organization>Ascenta Therapeutics</organization>
  </responsible_party>
  <keyword>at-101</keyword>
  <keyword>at101</keyword>
  <keyword>cancer</keyword>
  <keyword>hormone refractory</keyword>
  <keyword>prostate</keyword>
  <keyword>docetaxel</keyword>
  <keyword>prednisone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gossypol acetic acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

